HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 2, 2023

Rhea-AI Summary

Harmony Biosciences Holdings (NASDAQ: HRMY) announced that it will release its first quarter 2023 financial results on May 2, 2023, before the U.S. financial markets open. A conference call will be held on the same day at 8:30 a.m. ET to discuss the results. Investors can participate by dialing (800) 343-4136 for domestic calls or +1 (203) 518-9843 for international calls, referencing passcode HRMYQ123. The live and replayed webcast will be accessible on the company’s investor page.

Harmony Biosciences focuses on developing therapies for rare neurological diseases, emphasizing innovation and empathy. Established in 2017 and headquartered in Plymouth Meeting, PA, the company aims to improve the lives of patients suffering from these conditions.

Positive

• Scheduled release of first quarter 2023 financial results indicates transparency and ongoing communication with investors.
• Focus on rare neurological diseases highlights a niche market with potential for growth.

Negative

• None.

PLYMOUTH MEETING, Pa., April 20, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report first quarter 2023 financial results on Tuesday, May 2, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on May 2, 2023, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial (800) 343-4136 (domestic) or +1 (203) 518-9843 (international), and reference passcode HRMYQ123. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences 
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-report-first-quarter-2023-financial-results-on-may-2-2023-301802336.html

SOURCE Harmony Biosciences

FAQ

What date will Harmony Biosciences report its first quarter 2023 financial results?

Harmony Biosciences will report its first quarter 2023 financial results on May 2, 2023.

What time is the earnings conference call for Harmony Biosciences?

The earnings conference call for Harmony Biosciences is scheduled for 8:30 a.m. ET on May 2, 2023.

How can investors participate in the Harmony Biosciences earnings call?

Investors can participate by calling (800) 343-4136 domestically or +1 (203) 518-9843 internationally, using the passcode HRMYQ123.

Where can I find the webcast of Harmony Biosciences' earnings call?

The live and replayed webcast can be found on the investor page of Harmony Biosciences' website.